- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03071653
Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study (LCSD)
Left Cardiac Sympathetic Denervation (LCSD) for Cardiomyopathy Feasibility Pilot Study
Study Overview
Status
Intervention / Treatment
Detailed Description
STUDY SUMMARY
TITLE Left Cardiac Sympathetic Denervation (LCSD) for Cardiomyopathy Study DESIGN Phase II feasibility parallel randomised controlled trial (RCT) AIMS Assess the feasibility and safety of LCSD in patients with cardiomyopathy and heart failure OUTCOME MEASURES Recruitment rates, retention, follow-up and safety POPULATION 30 patients with heart failure secondary to cardiomyopathy ELIGIBILITY Adult participants with ischemic and non-ischemic cardiomyopathy DURATION 18 months follow up
METHODS:
Participants will be randomized to receive LCSD in addition to optimal medical therapy in the intervention arm (15 patients) and optimal medical therapy in the active control arm (15 patients). Participants would be recruited from both inpatient and outpatient general medical and cardiology wards and clinics at Groote Schuur Hospital where patients with the syndrome of heart failure are frequently referred for subspecialty evaluation and management. Eligible patients who meet the inclusion criteria would be randomized to undergo LCSD in addition to optimal medical therapy (intervention arm) or receive standard optimal medical therapy (active placebo). Optimal therapy for patients with cardiomyopathy and heart failure currently consists of an ace-inhibitor or angiotensinogen receptor blocker, beta-blocker, mineralocorticoid receptor antagonist with or without a loop diuretic, and digoxin. All patients in the study would receive an implantable loop recorder to allow for the accurate determination of episodes of symptomatic and asymptomatic ventricular tachyarrhythmias. In order not to lose all of the clinical outcome information obtained in the pilot phase of the study, we would propose only assessing the pre-specified feasibility and safety aspects of the study and keeping the data on efficacy outcomes blinded for inclusion in the fully powered main study.
The LCSD procedure The procedure involves the surgical removal of the lower half of the left stellate ganglion (T1) and thoracic ganglia (T2-T4), thereby removing the pro-arrhythmic noradrenergic input to the ventricles (3). LCSD raises the ventricular fibrillation threshold without impairing cardiac contractility or reducing heart rate. LCSD results in pre-ganglionic denervation, thus preventing re-innervation and producing permanent antifibrillatory effects. This procedure can be performed by video-assisted thoracoscopic surgery (VATS) usually in less than 45 minutes and will be conducted by thoracic surgeons at Groote Schuur Hospital. The lead thoracic surgeon (J.R.) has a large experience in performing this procedure for the indication of hyperhidrosis in over 200 patients (personal communication). This experienced thoracic surgeon will lead a team of thoracic surgeons (T.P., L.M.) to perform the procedure.
Implantable loop recorder (ILR) insertion The implantable loop recorder is a small device that will be inserted at the end of the LCSD procedure by the thoracic surgeon or after enrolment in the optimal medical therapy arm by a cardiologist. This loop recorder is inserted under sterile conditions in the catheter laboratory or operating theatre. In the catheter laboratory, the device is inserted under local anaesthetic, subcutaneously over the left precordium and usually takes less than 15 minutes. The implantable loop recorder is a well-established device to quantify and detect atrial and ventricular tachyarrhythmias with an excellent safety record. The device has a battery life of up to 3 years and can be removed via a small skin incision at the end of the study. Implantable loop recorder insertion does not carry risk of known major complications. There is a minimal risk (<1%) of complications (infection, bleeding) as the device is implanted subcutaneously. Potential complications include superficial skin infections that readily responds to antibiotics. Device removal is easy to perform and is seldom required.
Optimal Medical Therapy
All eligible patients with heart failure and depressed left ventricular systolic function will receive guideline and evidence based optimal tolerated medical therapy. The level of risk associated with optimal medical therapy is considered very low. For the majority of patients with heart failure and depressed left ventricular systolic function this will include:
- A renin angiotensin system blocker at highest tolerated doses (e.g., enalapril 10mg twice daily or equivalent)
- A mineralocorticoid receptor antagonist (e.g., Spironolactone 25-50mg daily or equivalent)
- A Beta-blocker (e.g., Carvedilol 25mg twice daily or equivalent)
- The use of a loop diuretic and digitalis will be clinically driven and used at the discretion of the attending clinician
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Western Cape
-
Cape Town, Western Cape, South Africa, 7925
- University of Cape Town
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least 18 years of age
- New York Heart Association (NYHA) II/III stable heart failure due to an ischemic or non-ischemic cardiomyopathy with a Left Ventricular Ejection Fraction <=35% based on Echocardiogram, ERNA or MRI performed in the last 12 months. For the purpose of this study, Ischemic cardiomyopathy will be defined as Left Ventricular systolic dysfunction (Ejection Fraction <35%) associated with 75% narrowing of at least 1 of the 3 major coronary arteries, a documented history of a ST elevation myocardial infarction or significant regional wall motion abnormality on an echocardiogram. Non-ischemic cardiomyopathy will be defined as Left Ventricular systolic dysfunction <35% in the absence of known coronary artery disease or regional wall motion abnormality on echocardiography.
- No history of a prior cardiac arrest or sustained (>30 seconds or <30s if haemodynamically unstable) ventricular tachyarrhythmia.
- Signed informed consent forms will be available in IsiXhosa, Afrikaans and English.
Exclusion Criteria:
- History of prior unexplained syncope, sudden cardiac arrest or ventricular arrhythmia
- Peripartum cardiomyopathy or cardiomyopathy associated with thyrotoxicosis
- History of coronary revascularization or percutaneous intervention in the preceding 3 months
- Myocardial infarction in the preceding 1 month
- NYHA IV at enrollment
- Patient taking an antiarrhythmic drug (not including beta-blockers)
- Pregnancy
- Any non-cardiac condition that is associated with a high likelihood of death during the trial such as major organ dysfunction or malignancy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Left Cardiac Sympathetic Denervation (LCSD)
Left Cardiac Sympathetic Denervation (LCSD) in addition to Optimal Medical Therapy (OMT)
|
The procedure involves the surgical removal of the lower half of the left stellate ganglion (T1) and thoracic ganglia (T2-T4), thereby removing the pro-arrhythmic noradrenergic input to the ventricles
All eligible patients with heart failure and depressed left ventricular systolic function will receive guideline and evidence based optimal tolerated medical therapy. The level of risk associated with optimal medical therapy is considered very low. For the majority of patients with heart failure and depressed left ventricular systolic function this will include:
|
Other: OMT only
Optimal Medical Therapy (OMT) only
|
All eligible patients with heart failure and depressed left ventricular systolic function will receive guideline and evidence based optimal tolerated medical therapy. The level of risk associated with optimal medical therapy is considered very low. For the majority of patients with heart failure and depressed left ventricular systolic function this will include:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of recruiting
Time Frame: 36 months
|
Recruitment rate
|
36 months
|
Feasibility of performing the procedure in recruited patients
Time Frame: 36 months
|
Patient retention
|
36 months
|
Procedure related complications
Time Frame: 36 months
|
Measured by:• Horner's syndrome in those under going LCSD • Pneumothorax in those undergoing LCSD • Implantable loop recorder site sepsis
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality and morbidity
Time Frame: 36 months
|
Measured by: All cause mortality; Heart failure related mortality; Hospital admissions; Ventricular arrhythmias;
|
36 months
|
Functional capacity: Measured by 6 minute walk test Quality of life at 6 months Admission to hospital for heart failure Functional Capacity
Time Frame: 6 monthly for 36 months
|
Measured by 6 minute walk test
|
6 monthly for 36 months
|
Functional capacity: Quality of life (EQ-5D questionnaire) Quality of life at 6 months Admission to hospital for heart failure Functional Capacity
Time Frame: 6 monthly for 36 months
|
Quality of life (EQ-5D questionnaire)
|
6 monthly for 36 months
|
End Systolic and Diastolic volumes
Time Frame: 6 monthly for 36 months
|
End Systolic and Diastolic volumes as determined by Echocardiography
|
6 monthly for 36 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 001001001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dilated Cardiomyopathy
-
Bristol-Myers SquibbTerminatedPrimary Familial Dilated CardiomyopathyUnited States, Germany, Spain, United Kingdom
-
Hospital General Universitario Gregorio MarañonMinisterio de Sanidad, Servicios Sociales e IgualdadUnknownPrimary Idiopathic Dilated CardiomyopathySpain
-
Nantes University HospitalCompleted
-
IRCCS SYNLAB SDNCompletedPatients With Ischemic or Idiopathic Dilated CardiomyopathyItaly
-
Capricor Inc.National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaboratorsUnknownHeart Failure | Ischemic Cardiomyopathy | Nonischemic Cardiomyopathy | Dilated Cardiomyopathy (DCM)United States
-
Ray HershbergerNational Heart, Lung, and Blood Institute (NHLBI); National Human Genome Research...Active, not recruiting
-
University of TehranCompletedDilated CardiomyopathyIran, Islamic Republic of
-
McGill University Health Centre/Research Institute...Unknown
-
Chung Shan Medical UniversityCompletedPediatric Dilated CardiomyopathyTaiwan
-
Qingdao UniversityUnknownDilated CardiomyopathyChina
Clinical Trials on Left Cardiac Sympathetic Denervation (LCSD)
-
Cindy HallWithdrawnSudden Cardiac DeathAustralia
-
Henan Institute of Cardiovascular EpidemiologyCompletedPrimary Aldosteronism Due to Aldosterone Producing AdenomaChina
-
University of California, Los AngelesOregon Health and Science UniversityRecruitingVentricular Fibrillation | Ventricular Tachycardia | Sudden Cardiac Death | CardiomyopathyUnited States
-
Charles University, Czech RepublicMount Sinai Hospital, New York; General University Hospital, Prague; Na Homolce...UnknownArterial Hypertension | Chronic Renal InsufficiencyCzech Republic
-
Heart of England NHS TrustCompletedHypertension | Chronic Kidney DiseaseUnited Kingdom
-
National Institute of Cardiology, Laranjeiras,...CompletedArterial Hypertension | Resistant Arterial HypertensionBrazil
-
Vivek ReddyCompletedVentricular TachycardiaUnited States, Czechia
-
The Second Affiliated Hospital of Chongqing Medical...Chongqing Medical University; Jiangsu Provincial People's HospitalUnknown
-
Heart Center Leipzig - University HospitalCompletedTherapy Resistant Arterial HypertensionGermany
-
Vivek ReddyCompletedVentricular TachycardiaUnited States, Czechia, Russian Federation